BR112014015333A2 - composições lipossomais de clorito ou clorato - Google Patents
composições lipossomais de clorito ou cloratoInfo
- Publication number
- BR112014015333A2 BR112014015333A2 BR112014015333A BR112014015333A BR112014015333A2 BR 112014015333 A2 BR112014015333 A2 BR 112014015333A2 BR 112014015333 A BR112014015333 A BR 112014015333A BR 112014015333 A BR112014015333 A BR 112014015333A BR 112014015333 A2 BR112014015333 A2 BR 112014015333A2
- Authority
- BR
- Brazil
- Prior art keywords
- chlorite
- chlorate
- liposomal compositions
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
resumo patente de invenção: "composições lipossomais de clorito ou clorato". a presente invenção refere-se a lipossomas e as composições lipossomais que compreendem clorito, clorato ou uma mistura dos mesmos, aprisionada dentro do núcleo do lipossoma, os métodos para a sua preparação e os métodos de uso, em particular, como medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579326P | 2011-12-22 | 2011-12-22 | |
PCT/IB2012/057645 WO2013093891A1 (en) | 2011-12-22 | 2012-12-21 | Liposomal chlorite or chlorate compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014015333A8 BR112014015333A8 (pt) | 2017-06-13 |
BR112014015333A2 true BR112014015333A2 (pt) | 2017-06-13 |
Family
ID=47630448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014015333A BR112014015333A2 (pt) | 2011-12-22 | 2012-12-21 | composições lipossomais de clorito ou clorato |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130177629A1 (pt) |
EP (1) | EP2793860A1 (pt) |
JP (1) | JP2015502400A (pt) |
CN (1) | CN104125826A (pt) |
AU (1) | AU2012297589C1 (pt) |
BR (1) | BR112014015333A2 (pt) |
CA (1) | CA2857604A1 (pt) |
IN (1) | IN2014DN05866A (pt) |
MX (1) | MX2014007664A (pt) |
RU (1) | RU2014130080A (pt) |
WO (1) | WO2013093891A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1962805T3 (pl) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
WO2014037927A1 (en) * | 2012-09-10 | 2014-03-13 | Nuvo Research Gmbh | Chlorate compositions and use of chlorate for treating radiation exposure |
CA2891487A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
US20140271815A1 (en) * | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
US9603799B2 (en) | 2013-03-15 | 2017-03-28 | Htd Biosystems Inc. | Liposomal vaccine adjuvants and methods of making and using same |
PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
JP6900596B2 (ja) * | 2015-08-20 | 2021-07-07 | フリードリッヒ − ヴィルヘルム キューネ | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
CN108883069B (zh) * | 2016-01-04 | 2021-07-20 | 中央研究院 | 基于酯化/皂化的用于微脂体负载的方法 |
WO2019075202A2 (en) * | 2017-10-11 | 2019-04-18 | California Institute Of Technology | METHODS AND SYSTEM FOR INTERFERING WITH THE VIABILITY OF BACTERIA, ASSOCIATED ANTIMICROBIALS, AND COMPOSITIONS |
WO2019160519A2 (en) * | 2018-02-15 | 2019-08-22 | Yeditepe Universitesi | Exosome isolation method by two phase fluid system |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
CN110563829B (zh) * | 2019-09-17 | 2021-03-26 | 中国人民解放军国防科技大学 | 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用 |
CN112716973A (zh) * | 2019-10-28 | 2021-04-30 | 卢序 | 一种降低细胞还原应激的氧化剂的用途 |
TR202012260A2 (tr) * | 2020-08-05 | 2020-10-21 | Emin Zuemruetdal | Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu |
WO2023225125A1 (en) * | 2022-05-19 | 2023-11-23 | Neuvivo, Inc. | Biomarkers for neurogenerative disease |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
DE3213389A1 (de) | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
US4551288A (en) | 1982-08-16 | 1985-11-05 | Sandoz, Inc. | Processes for the preparation of liposome drug delivery systems |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4574084A (en) | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
DE3515745A1 (de) | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
JPH0751496B2 (ja) | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
DE3625867C2 (de) | 1986-07-31 | 1995-10-19 | Elstner Erich F Prof Dr | Verwendung von Tetrachlordecaoxid in der Ophthalmologie |
US4781871A (en) | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
US4752425A (en) | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
EP0414663A4 (en) | 1987-04-16 | 1991-07-17 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
US5049390A (en) | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
US4851222A (en) | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
US5269979A (en) | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
US5190822A (en) | 1990-04-20 | 1993-03-02 | Fuji Photo Film Co., Ltd. | Surface-modifiable liposome and process for producing surface-modified liposome |
US5206027A (en) | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
WO1992007959A1 (en) | 1990-11-05 | 1992-05-14 | Biowhittaker Inc. | Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations |
US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
JPH06206825A (ja) | 1992-12-11 | 1994-07-26 | Nippon Rooshiyon Kk | 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤 |
DE59406065D1 (de) | 1993-03-24 | 1998-07-02 | Ciba Geigy Ag | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
CA2179014C (en) | 1993-12-17 | 2003-07-29 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US6110666A (en) | 1994-06-09 | 2000-08-29 | Medical Research Council | Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure |
US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
JP3735921B2 (ja) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb・脂質複合体およびその用途 |
US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
CN1152691C (zh) | 1997-10-06 | 2004-06-09 | 奥克索化学有限公司 | 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 |
US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
CN1904055A (zh) | 1997-11-19 | 2007-01-31 | 乔治敦大学 | 定向脂质体基因送递 |
US6573101B1 (en) | 1998-02-12 | 2003-06-03 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US6251372B1 (en) | 1998-02-27 | 2001-06-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6132702A (en) | 1998-02-27 | 2000-10-17 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6077502A (en) | 1998-02-27 | 2000-06-20 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6350438B1 (en) | 1998-02-27 | 2002-02-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
DE69923987T2 (de) * | 1998-10-08 | 2006-11-02 | Karagoezian, Hampar L., San Juan Capistrano | Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten |
JP4727816B2 (ja) * | 1998-10-08 | 2011-07-20 | エル. カラジョージアン、ハンパー | 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤 |
JP2001002592A (ja) | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
EP1408994A2 (en) | 1999-08-18 | 2004-04-21 | OXO Chemie AG | Chemically-stabilized chlorite solutions for treating cancer |
CN1376313A (zh) | 1999-08-27 | 2002-10-23 | 马克罗尼克斯美国公司 | 用于双位存储的非易失性存储器结构及其制造方法 |
US20070104798A1 (en) * | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
DE60041351D1 (de) | 1999-11-24 | 2009-02-26 | Transave Inc | Gssytem |
EP1246606A2 (en) | 1999-12-30 | 2002-10-09 | Judith K. Gwathmey | Iron chelator delivery system |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US7101985B2 (en) | 2001-11-20 | 2006-09-05 | Baylor College Of Medicine | Methods and compositions in checkpoint signaling |
US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
KR20030072766A (ko) * | 2002-03-06 | 2003-09-19 | (주)인터커머스 | 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법 |
US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
JP3415131B1 (ja) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
US8765808B2 (en) * | 2005-03-23 | 2014-07-01 | Chs Pharma, Inc. | Treatment or prevention of cancer and precancerous disorders |
EP1906977B1 (en) | 2005-07-21 | 2012-02-22 | Nuvo Research AG | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
CA2919344C (en) * | 2005-12-22 | 2017-02-28 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
EP1971426A1 (de) | 2006-01-11 | 2008-09-24 | P & W Invest Vermögensverwaltungsgesellschaft mbH | Hüllenmembran zur abgabe eines eingeschlossenen wirkstoffs, ein verfahren zur herstellung sowie deren verwendung |
US8252343B2 (en) | 2007-06-01 | 2012-08-28 | Nuvo Research Ag | Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
US20110052655A1 (en) | 2007-08-08 | 2011-03-03 | Wilson Kurt Whitekettle | Methods and vesicles for controlling protozoa |
JP5766188B2 (ja) * | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
US20110177147A1 (en) | 2010-01-21 | 2011-07-21 | General Electric Company | Stable biocidal delivery systems |
-
2012
- 2012-12-21 CA CA2857604A patent/CA2857604A1/en not_active Abandoned
- 2012-12-21 AU AU2012297589A patent/AU2012297589C1/en not_active Ceased
- 2012-12-21 MX MX2014007664A patent/MX2014007664A/es unknown
- 2012-12-21 BR BR112014015333A patent/BR112014015333A2/pt not_active IP Right Cessation
- 2012-12-21 CN CN201280070434.8A patent/CN104125826A/zh active Pending
- 2012-12-21 JP JP2014548324A patent/JP2015502400A/ja active Pending
- 2012-12-21 WO PCT/IB2012/057645 patent/WO2013093891A1/en active Application Filing
- 2012-12-21 US US13/724,963 patent/US20130177629A1/en not_active Abandoned
- 2012-12-21 RU RU2014130080A patent/RU2014130080A/ru not_active Application Discontinuation
- 2012-12-21 IN IN5866DEN2014 patent/IN2014DN05866A/en unknown
- 2012-12-21 EP EP12820937.6A patent/EP2793860A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IN2014DN05866A (pt) | 2015-05-22 |
EP2793860A1 (en) | 2014-10-29 |
US20130177629A1 (en) | 2013-07-11 |
BR112014015333A8 (pt) | 2017-06-13 |
JP2015502400A (ja) | 2015-01-22 |
AU2012297589A1 (en) | 2013-07-11 |
AU2012297589B2 (en) | 2014-10-30 |
RU2014130080A (ru) | 2016-02-10 |
CA2857604A1 (en) | 2013-06-27 |
CN104125826A (zh) | 2014-10-29 |
MX2014007664A (es) | 2015-05-11 |
AU2012297589C1 (en) | 2015-04-16 |
WO2013093891A1 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014015333A8 (pt) | composições lipossomais de clorito ou clorato | |
BR112014016165A8 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
BR112014011594A2 (pt) | anticorpos anti-il-36r | |
NZ732777A (en) | Ionizable cationic lipid for rna delivery | |
BR112015008480A2 (pt) | compostos de benzeno substituído | |
BR112015001327A2 (pt) | complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos | |
CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
BR112014000236A2 (pt) | lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas | |
BR112014013175A2 (pt) | composições de liberação prolongada baseadas em lipídios anfipáticos | |
BR112014010291A2 (pt) | composições de lipossoma combinacionais para terapia de câncer | |
BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112013018877A2 (pt) | composições farmacêuticas que compreendem anticorpos humanos para pcsk9 | |
BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
BR112013020265A2 (pt) | formas de rifaximina e uso das mesmas | |
BR112012007322A2 (pt) | composto de 2-piridona usados como inibidores de neutrófilo elastase | |
BR112014004651A2 (pt) | composto de pirazol e uso farmacêutico do mesmo | |
BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
BR112012012862A2 (pt) | composição farmacêutica compreendendo oligopeptídeos | |
BR112014010174A2 (pt) | uso de uma composição para a fabricação de um produto para melhorar a função executiva de um indivíduo e para tratar o mesmo | |
PE20150353A1 (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |